# US 2017/0360721 A1 · Hydroxynaphthoquinone compounds for treatment of non-small cell lung cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0360721 A1
- Document ID: US20170360721A1
- Status: Published application
- Kind: A1
- Application number: 15/186,795
- Filed: 2016-06-20
- Published: 2017-12-21
- Earliest claimed: 2016-06-20
- Assignees: Macau University of Science and Technology
- Applicants: Macau University of Science and Technology
- Inventors: Liang Liu; Lai Han Leung; Xia Li; Xing-Xing Fan
- Web page: https://patentgrep.com/patent/US20170360721A1

## CPC

- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A compound suitable for treating EGFR-dependent non-small cell lung cancer exceptionally inhibits activity of the EGFR kinase, in particular in EGFR-dependent non-small cell lung cancer with intrinsic or acquired resistance against at least one EGFR inhibitor. Methods for inhibiting EGFR kinase activity in non-small cell lung cancer cells which harbor an abnormality in the EGFR gene and for targeting cancer cells harboring an abnormality in EGFR gene by contacting EGFR-dependent non-small cell lung cancer cells with said compound are also provided. The compounds allow for an advantageous inhibition of the EGFR kinase activity and induction of apoptosis of the non-small cell lung cancer cells with abnormality in the EGFR gene. Hence, said compounds represent a highly promising treatment option for patients harboring EGFR-dependent cancer.

## Claims

### Claim 1

A method of treating a subject suffering from EGFR-dependent non-small cell lung cancer comprising administering an effective amount of a hydroxynaphthoquinone compound of Formula (I) or a pharmaceutically acceptable salt, solvate or anhydrate thereof to the subject:
wherein R is selected from —H, —OH,
wherein the EGFR-dependent non-small cell lung cancer have an intrinsic or acquired resistance against at least one of gefitinib, erlotinib and/or afatinib.

### Claim 2

A method of inhibiting EGFR kinase activity in non-small cell lung cancer cells harboring an abnormality in the EGFR gene comprising administering an effective amount of a hydroxynaphthoquinone compound of Formula (I) or a pharmaceutically acceptable salt, solvate or anhydrate thereof:
wherein R is selected from —H, —OH,
to a subject suffering from EGFR-dependent non-small cell lung cancer,
wherein the non-small cell lung cancer cells have an intrinsic or acquired resistance against at least one of gefitinib, erlotinib and/or afatinib.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the compound is a compound of Formula (II):

### Claim 4 (depends on 1, 2)

The method of claim 1 or 2, wherein the compound is a compound of Formula (IIa):

### Claim 5 (depends on 1, 2)

The method of claim 1 or 2, wherein the non-small cell lung cancer is an adenocarcinoma.

### Claim 6 (depends on 1)

The method of claim 1, wherein the subject is a human and wherein the non-small cell lung cancer comprises cancer cells harboring an abnormality in the EGFR gene resulting from at least one of an exon 19 deletion and/or an exon 21 substitution.

### Claim 7 (depends on 6)

The method of claim 6, wherein the subject is a human and wherein the cancer cells harboring an abnormality in the EGFR gene have an intrinsic or acquired resistance at least against gefitinib and/or erlotinib.

### Claim 8 (depends on 7)

The method of claim 7, wherein the abnormality in the EGFR gene results from at least one of E746-A750del deletion in exon 19 and/or T790M substitution in exon 20.

### Claim 9 (depends on 2)

The method of claim 2, wherein the subject is a human and the EGFR-dependent non-small cell lung cancer cells harbor an abnormality in the EGFR gene resulting from at least one of an exon 19 deletion and/or exon 21 substitution and wherein the EGFR-dependent non-small cell lung cancer cells have an intrinsic or acquired resistance at least against gefitinib and/or erlotinib.

### Claim 10 (depends on 9)

The method of claim 9, wherein the abnormality in EGFR gene results from at least one of E746-A750del deletion in exon 19 and/or T790M substitution in exon 20.

### Claim 11 (depends on 1, 2)

The method of claim 1 or 2, wherein the compound is administered in form of a pharmaceutical composition comprising the compound and at least one pharmaceutically acceptable excipient selected from at least one of a diluent, a filler, a binder, a disintegrant, a lubricant, a coloring agent, a surfactant or a preservative.

### Claim 12

A method of targeting non-small cell lung cancer cells harboring an abnormality in the EGFR gene comprising the step of contacting said cells with a hydroxynaphthoquinone compound of Formula (I) or a salt, solvate or anhydrate thereof:
wherein R is selected from —H, —OH,
wherein the non-small cell lung cancer cells have an intrinsic or acquired resistance against at least one of gefitinib, erlotinib and/or afatinib.

### Claim 13 (depends on 12)

The method of claim 12, wherein apoptosis of the non-small cell lung cancer cells is induced.

### Claim 14 (depends on 12)

The method of claim 12, wherein the non-small cell lung cancer cells are from an adenocarcinoma.

### Claim 15 (depends on 12)

The method of claim 12, wherein the abnormality in the EGFR gene results from at least one of an exon 19 deletion and/or an exon 21 substitution and wherein the non-small cell lung cancer cells harboring an abnormality in the EGFR gene have an intrinsic or acquired resistance at least against gefitinib and/or erlotinib.

### Claim 16 (depends on 15)

The method of claim 15, wherein the compound has an IC50 on the non-small cell lung cancer cells harboring an abnormality in the EGFR gene of at most 5 μM and an IC50 on non-cancerous lung cells being at least 2 times higher than the IC50 on said non-small cell lung cancer cells.

### Claim 17 (depends on 12)

The method of claim 12, wherein the compound is used in a concentration of at least 1 μM.

### Claim 18 (depends on 12)

The method of claim 12, wherein the compound is a compound having Formula (II):
and wherein the concentration of the compound of Formula (II) is at least 2 μM.

### Claim 19 (depends on 12)

The method of claim 12, wherein the compound is a compound having Formula (IIa):
and wherein the concentration of the compound of Formula (IIa) is at least 3 μM.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cancer cells are contacted with the compound for at least 12 h.
